公开(公告)号：US11319279B2

公开(公告)日：2022-05-03

申请号：US17092949

申请日：2020-11-09

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Won Gon Kim ,  Hyun Ju Kim ,  Yu Jin Kim ,  Kyung Yun Cho

IPC: C07C235/64 ,  C07C233/75 ,  C07C235/56 ,  C07C237/42 ,  A61K31/166 ,  A61K31/135 ,  A61K45/06 ,  A61K35/66

Abstract: The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof.
The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

公开(公告)号：US20170204052A1

公开(公告)日：2017-07-20

申请号：US15311245

申请日：2015-05-14

Applicant: Korea Research Institute of Bioscience and Biotechnology

Inventor： Won Gon Kim ,  Hyun Ju Kim ,  Yu Jin Kim ,  Kyung Yun Cho

IPC: C07C233/75 ,  A61K45/06 ,  A61K31/135

CPC classification number: C07C233/75 ,  A61K31/135 ,  A61K31/166 ,  A61K35/66 ,  A61K45/06 ,  C07C235/56 ,  C07C235/64 ,  C07C237/42 ,  Y02A50/481

Abstract: The present invention relates to: coralmycin A and B, which are novel compounds exhibiting antimicrobial activity, an isomer thereof, a derivative thereof or a pharmaceutically acceptable salt thereof; a microorganism of the genus Corallococcus producing the same; and an antimicrobial use thereof.The coralmycin A and B have very strong antimicrobial activity against antibiotic-resistant bacteria such as MRSA, QRSA, VRE, VISA, etc.; Acinetobacter baumannii, which is a multidrug-resistant microorganism; and also against gram-positive microorganisms and gram-negative microorganisms. Therefore, the present invention can be very useful for prevention, treatment and alleviation of various microbial infections, and thus can be widely applied to the medical supply, quasi-drug, food, and feed industries.

公开(公告)号：US20140142173A1

公开(公告)日：2014-05-22

申请号：US14009526

申请日：2011-11-28

Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

Inventor： Won Gon Kim ,  Baek Soo Han ,  Kyoung Shim Kim ,  Kwang Soo Kim ,  Young Mi Kang ,  Yu Jin Kim ,  Chun Hyung Kim ,  Mi Jin Sohn ,  Hoe Yune Jung

IPC: A61K31/357 ,  A61K36/83

CPC classification number: A61K31/357 ,  A61K36/83

Abstract: The present invention relates to: a pharmaceutical composition or a Nurr1 activating composition for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the composition comprises an active ingredient in the form of genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; or a functional food additive for preventing or alleviating a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the additive comprises genkwanin N or yuanhuacine, a Daphne genkwa extract comprising one or more of the above compounds, or a fraction thereof; and a method for the prevention or treatment of a neurodegenerative disease or a disease induced by impaired Nurr1 function, wherein the method comprises the step of administering the pharmaceutical composition.

Abstract translation: 本发明涉及：用于预防或治疗神经退行性疾病或由Nurr1功能受损引起的疾病的药物组合物或Nurr1活化组合物，其中所述组合物包含以genkwanin N或元花胺形式的活性成分，达芙妮 genkwa提取物包含一种或多种上述化合物或其一部分; 或用于预防或减轻神经退行性疾病或由Nurr1功能受损引起的疾病的功能性食品添加剂，其中所述添加剂包括genkwanin N或元华辛，包含一种或多种上述化合物的Daphne genkwa提取物或其一部分; 以及用于预防或治疗由Nurr1功能受损引起的神经变性疾病或疾病的方法，其中所述方法包括施用所述药物组合物的步骤。